CD274 and neoplasm: Indeed, a positive response to anti-PD-L1 therapy has been associated with high expression of PD-L1 on tumor-infiltrating immune cells across multiple cancer types, indicating a role for PD-L1+ immune cells in suppressing anti-tumor responses, which are re-invigorated on blockade of PD-L1 signaling (49).